APTA Share Price Performance
SEK 0.62
-0.87 (-58.25%)
Price SEK 0.62
Share Pricen/a
Aptahem AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
APTA Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Aptahem AB (publ) Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.31
- 100.00%
- -251.07%
- 0%
About APTA
- Founded
- 2014
- Employees
- 3
- CEO
- WebsiteView website
Aptahem AB (publ), a biotechnology company, engages in the development of ribonucleic acid-based pharmaceuticals in Sweden. The company’s lead product candidate is Apta-1, which is in Phase I clinical trial for the treatment of patients with sepsis/septic shock and severe inflammatory conditions, as well as to prevent organ and tissue damages in life-threatening conditions. It also develops Apta-2 which is in preclinical stage for the treatment of inflammation; and Apta-3 which is in discovery stage. The company has a collaboration with Hongene Biotech for the manufacturing of RNA and oligonucleotides. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
